Hereditary Leiomyomatosis and Renal Cell Carcinoma

Explore clinical trials studying Hereditary Leiomyomatosis and Renal Cell Carcinoma. Study availability and eligibility vary by location and protocol.

2 public trials 1 recruiting study

Refine in advanced search Browse all conditions

Hereditary Leiomyomatosis and Renal Cell Carcinoma trial results

Recruiting

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

NCT04981509

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +21 more
Locations: UC San Diego Moores Cancer Center La Jolla, California, United States

Emory University Hospital Midtown Atlanta, Georgia, United States

Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States

Emory Saint Joseph's Hospital Atlanta, Georgia, United States

View all 13 locations

View Trial Details

Not Yet Recruiting

Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer

NCT07716735

Conditions: Adenocarcinoma, Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma, +28 more
Locations: UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California, United States

View Trial Details

Hereditary Leiomyomatosis and Renal Cell Carcinoma

Hereditary Leiomyomatosis and Renal Cell Carcinoma trial results

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer

Related conditions